Varhaug et al. compared the utility of three serum biomarkers in mitochondrial disease—neurofilament light chain (NF-L), fibroblast growth factor-21 (FGF-21) and growth differentiation factor 15 (GDF-15). Here, NEFL is linked to inborn mitochondrial metabolism disorder.